Is Omeros Corporation (OMER) One of the Hot Stocks to Buy with Huge Upside Potential?

Group 1 - Omeros Corporation is identified as a hot stock with significant upside potential, with H.C. Wainwright raising its price target from $9 to $20 while maintaining a Buy rating [1][2] - The company has entered into an asset purchase and license agreement with Novo Nordisk for zaltenibart, which is expected to enhance its market position [1][3] - Omeros will receive an upfront cash payment of $240 million, with additional potential payments of $510 million tied to development and approval milestones, and up to $1.3 billion in sales-based milestone payments [2] Group 2 - Omeros is a clinical-stage biopharmaceutical company focused on developing small-molecule and protein therapeutics for immunologic diseases [4] - Novo Nordisk operates in the pharmaceutical sector, specializing in diabetes, obesity care, and rare diseases, indicating a strong partnership potential for Omeros [3]